January 24, 2018

Fischer et al. accepted for publication in Arthritis & Rheumatology

Selective activation of tumor necrosis factor receptor 2 induces anti-inflammatory responses and alleviates experimental arthritis.

Fischer R, Proske M, Duffey M, Stangl H, Martinez GF, Peters N, Kraske A, Straub RH, Bethea JR, Kontermann RE, Pfizenmaier K.



Regulatory T cells (Tregs) modulate immune responses and can suppress the development of autoimmune diseases. Tumor necrosis factor receptor 2 (TNFR2) has been recognized as a key receptor on these cells that facilitates expansion and stabilization of CD4 + Tregs. Here, we investigated the therapeutic activity of a novel TNFR2 agonist in experimental arthritis and the role of different Treg subsets.


A novel mouse TNFR2-selective fusion protein (EHD2-sc-mTNF R 2 ) was generated by genetic engineering. Mouse T cells were incubated together with IL-2 and/or EHD2-sc-mTNF R 2 and effects on Tregs were analyzed by flow cytometry. Then mice with collagen induced arthritis were treated with EHD2-sc-mTNF R 2 or saline and therapeutic effect was monitored and characterized.


Selective activation of TNFR2 does expand both, CD4 + as well as CD8 + Tregs. Moreover, TNFR2 activation elevated the number of CD4 + CD25 + Tregs, but not CD8 + CD25 + Tregs, and increased the number of FoxP3-expressing cells in CD8 + Tregs, but not CD4 + Tregs, implying different mechanisms of TNFR2-induced expansion of diverse T cell subsets with suppressive activity. Using the collagen induced arthritis model, we demonstrate that administration of the TNFR2 agonist EHD2-sc-mTNF R 2 leads to the expansion of both CD4 + and CD8 + Tregs in vivo and induces anti-inflammatory responses that alleviate arthritis.


Summarizing, our data argue for the use of TNFR2-selective therapeutics as an effective approach in treating arthritic disease and possibly other inflammatory and autoimmune diseases. This article is protected by copyright. All rights reserved.

To the top of the page